Medtronic News
27 articles
growth-positive
Medtronic and Manchester NHS Trust sign healthtech co-development agreement
Medtronic has entered into a partnership with the Manchester University NHS Foundation Trust (MFT) to co-develop healthcare technologies, including robotic surgery and AI-related initiatives. This UK-first Research, Development, and Innovation (RDI) agreement aims to enhance collaboration on research and innovation projects across various medical fields. The partnership builds on existing collaborations that have improved patient care and clinical outcomes. The agreement aligns with the UK Governments 10-year plan for the NHS, focusing on community-centered care and digital health services. The initiative will leverage Medtronics product portfolio to enhance remote patient monitoring and community care provisions. This collaboration is expected to pioneer breakthroughs in healthcare and accelerate innovative research projects.
Partners
growth-negative
Commentary: Trump’s trade war is hurting most sectors of the economy
The article discusses the negative impact of President Trumps tariffs on various sectors of the US economy, particularly highlighting the effects on companies within the S&P 500 index. It notes that tariffs have significantly increased costs for businesses, leading to reduced profits and price hikes. General Motors, for example, reported a $1.1 billion hit to profits in the second quarter due to tariffs. Other companies like Ford, Home Depot, and Walmart also face similar challenges, with increased costs and reduced profit margins. The article emphasizes the widespread economic damage caused by the tariffs, affecting both businesses and consumers.
Customers
growth-positive
Finance week ahead: Jackson Hole Symposium, UK inflation, Walmart, Palo Alto Networks and Baidu
The article discusses the upcoming earnings reports of several major companies, including Walmart, Palo Alto Networks, and Baidu. Baidu has recently entered into a partnership with Uber to deploy its autonomous cars on Ubers ride-hailing platform outside of the US and mainland China, which is a positive development for the company. The article also highlights the Jackson Hole Symposium, where central bankers will discuss economic policy, particularly focusing on labor markets and interest rates. The symposium is significant as it may provide insights into the US Federal Reserves future interest rate decisions amid rising inflation concerns.
Partners
growth-positive
Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk
The Saudi Arabia Blood Glucose Device Market is projected to grow significantly from US$ 143.96 million in 2024 to US$ 259.8 million by 2033, driven by a rising incidence of diabetes, increased health awareness, and government initiatives. Advances in Continuous Glucose Monitoring (CGM) systems and user-friendly glucometers are enhancing patient compliance. Key players in the market include Abbott Laboratories, Medtronic, and Dexcom Inc. The market is supported by urban centers like Riyadh and Jeddah, indicating strong potential in Saudi Arabia. Lifestyle issues such as lack of physical activity and high-calorie diets contribute to the high diabetes prevalence, prompting government campaigns for early detection and self-management.
growth-positive
This $125M Israeli Startup Is Building The World's First Cataract Robot To Solve A Global Crisis: 'There Is No Human Way To Close The Gap'
ForSight Robotics, an Israeli startup focused on automating cataract and eye surgery, has raised $125 million to advance its precision robotics platform, Oryom. The investment round was led by Eclipse Ventures, with notable participation from Fred Moll and Moshe Shoham. The company aims to address the growing gap in ophthalmic care due to an aging population and a declining number of ophthalmologists. ForSights Oryom platform utilizes AI-based algorithms and computer vision to enhance surgical precision. The company plans to begin clinical trials by the end of the year and is in early discussions with the FDA. The new funding will support the regulatory process.
InvestmentProduct Stage
growth-positive
Trump Trade: President said to weigh possible U.S. strike against Iran
The article discusses several key developments involving U.S. President Donald Trump. Notably, Trump plans to sign an executive order to delay enforcement of a law that could ban or force the sale of TikTok, allowing the platform to continue operating in the U.S. for another 90 days. This move is seen as growth-positive for TikTok as it provides more time to ensure data security and compliance. Additionally, the U.S. Senate has passed a bill to establish a regulatory framework for stablecoins, and there is growing support within the Trump administration for the use of psychedelics in mental health treatment. These developments could impact various publicly traded companies in the tech, cryptocurrency, and psychedelic sectors.
growth-negative
Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
Sarepta has been downgraded by H.C. Wainwright to Sell from Neutral, with a price target of $10, following the announcement of another death due to acute liver failure in a second non-ambulatory Duchenne muscular dystrophy patient treated with Elevidys. The company is suspending shipments of the drug to non-ambulatory DMD patients until an immunosuppressive regimen can be agreed upon with regulators and implemented. Piper Sandler also downgraded Sarepta to Neutral from Overweight, with a price target of $36, down from $70. These downgrades reflect concerns over the safety of Elevidys and the regulatory challenges facing Sarepta.
Product StageCustomers
growth-negative
Court rules 2009 deal included taxable intellectual property sale; Ventor seeks Supreme Court delay.
The Israeli Tax Authority has initiated asset seizures on Medtronic Ventor, a subsidiary of Medtronic, due to a tax debt of approximately $190 million. This debt arises from a 2009 transaction where Medtronic acquired Ventor, including its intellectual property, which was deemed taxable by a court ruling in June 2023. Medtronic Ventor has appealed the decision and is seeking to delay tax collection until the appeal is resolved. The company had been negotiating a settlement with the Tax Authority, but talks collapsed, leading to the current enforcement actions. Medtronic Ventor continues to generate royalty income from its patents despite the closure of its Israeli development activities in 2012.
Acquired-byLayoffs
growth-positive
The Next Frontier to Treat Cancer: Electricity
The Wall Street Journal reports on the innovative use of electricity as a potential treatment for various diseases, including rheumatoid arthritis and brain cancer. Scientists are exploring the application of electric fields and pulses to target these conditions, marking a new frontier in medical treatment. This research is still in the R&D phase, indicating a growth-positive impact for the company as it highlights cutting-edge developments in healthcare. The article underscores the potential of electricity in revolutionizing disease treatment, positioning it as a promising area of scientific inquiry.
growth-negative
Medical device giant Medtronic laying off 3% of Israeli workforce as part of global cutbacks | CTech
Medtronic, a medical device giant, is laying off 35 employees in Israel, which is about 3% of its workforce in the country. This move is part of a global restructuring plan and not related to the current activity in Israel. Most of the employees being laid off are from Mazor Robotics, a company Medtronic acquired in 2018 for $1.6 billion. In recent weeks, Medtronic has also laid off 44 workers in California and dozens more in Ireland. It is estimated that the layoffs will continue throughout the company.
LayoffsAcquisition
growth-negative
Medtronic to lay off dozens in Israel
Medtronic, a US medical devices giant, is undergoing a process of reorganization that will involve layoffs worldwide. CEO Geoff Martha explained in an email to employees that the company needs to reduce its workforce to position itself for sustainable growth in the future. The layoffs will vary by team, region, and country. Medtronic has over 1,200 employees in Israel and has acquired several companies in the country. The companys share price has fallen 23% over the past year, but rose by 3.94% after the announcement of the layoffs. There are no plans to completely close any of the development centers in Israel. The article was published on April 20, 2023.
Layoffs
growth-positive
התוכניות לישראל של מנכ"ל חברת המכשור הרפואי הגדולה בעולם
Medtronic CEO, Geoff Martha, has expressed his enthusiasm for the companys recent partnership with Israel. The medical technology giant is developing a collaboration program where Israel will be the first market for the companys new medical equipment. The goal is to gather data in Israel that will demonstrate the economic value of its products before introducing them to other countries, primarily the attractive home market, the United States. This idea is somewhat similar to the cooperation model of Pfizer and the Ministry of Health during the Corona period, except that this time it involves a whole range of products.
PartnersExpand
growth-positive
Medtronic announces co-promotion agreement with CathWorks, with path toward acquisition
Medtronic has entered into a strategic partnership agreement with CathWorks to transform how coronary artery disease (CAD) is diagnosed and treated. Medtronic will invest up to $75 million and co-promote CathWorks FFRangio System. Medtronic also has the option to acquire CathWorks for up to $585 million. The FFRangio System combines artificial intelligence and advanced computational science to obtain quick and reliable FFR values from routine angiograms, eliminating the need for invasive measurements. The partnership is expected to be neutral to Medtronics fiscal year 2023 earnings and neutral to accretive thereafter. The agreement aims to expand the reach of the FFRangio system globally.
Partners
growth-positive
Medtronic Israel names Arik Corcos as its new Country Director | CTech
Medtronic Israel has appointed Arik Corcos as its new Country Director. Corcos has been with Medtronic since 2011 and has held various senior management positions. Medtronic Israel, with around 1,000 employees, focuses on cardiovascular treatment, neuroscience, minimally invasive surgery, and diabetes. Medtronic has a market cap of over $137 billion and has been active in the Israeli market for many years, including the acquisitions of Nutrino for $100 million in 2019 and Mazor Robotics for $1.6 billion in 2018.
Management Changes
growth-neutral
כלכליסט - דף הבית - הודעת שגיאה
The article is about the website כלכליסט and its various sections and services. It provides financial news and information about the stock market. The article does not mention any specific events or developments related to the company.
Mazor Robotics $1.6 billion acquisition is 'beginning to pay off,' Medtronic CEO says
growth-positive
The Medical Market Should Focus on Value, Not Price, Says Medtronic Exec
Medtronic PLC, a medtech giant, has been focusing on acquisitions in Israel. It has eight Israeli subsidiaries and has invested in another 10 Israeli companies. Its biggest acquisition in Israel was surgical robotics company Mazor Robotics Ltd., valued at $1.7 billion. Medtronics country director in Israel, Yaron Itzhari, discusses the companys acquisition strategy, the importance of value-based decision-making in healthcare, and the role of data in the medical world. Itzhari also highlights the potential of personalized medicine and the significance of Israels medical data collection. Medtronic aims to be a market leader and sees acquisitions as a way to stay innovative.
AcquisitionInvestment
growth-positive
Medtronic buys Israeli nutrition data co Nutrino
Medtronic plc has acquired Nutrino Health Ltd., an Israeli nutrition-related data services, analytics, and technologies company. The financial details of the deal were not disclosed, but sources estimate it to be around $100 million. Nutrino will be integrated into Medtronics Diabetes Group, with the aim of improving clinical outcomes for people with diabetes. Medtronic will leverage Nutrinos food analysis infrastructure, nutrition science expertise, and AI-driven personalized insights to enhance its technology and future innovations. The acquisition is expected to close in Medtronics third fiscal quarter.
Acquisition
growth-positive
Medtronic Seeks Out Israeli Diabetes Treatment Companies
Medtronic is considering investments in Israel-based companies in the field of diabetes treatment. The company is looking at three main clusters of technologies: blood glucose level tracking technologies, automatic injection of insulin, and technologies making use of data and artificial intelligence. In October, Medtronic announced the acquisition of Israel-based Mazor Robotics in a deal valued at $1.64 billion. Medtronic has made several previous acquisitions in Israel.
Acquisition
growth-positive
Israel grants $33 million to GE, Medtronic, Change Healthcare to boost R&D
Three multinational companies, Medtronic, GE Healthcare, and Change Healthcare, have received a government grant of 120 million shekels ($33 million) from the Israeli government. The grant aims to boost the presence of large companies in Israel and establish the country as a hub in biotechnology and medicine. The companies will use the grants to expand their research and development centers in Israel, which is expected to generate significant future tax income and create high-quality jobs in engineering and manufacturing. The program is part of an effort to promote digital health and inject new intellectual property into Israel.
PartnersInvestment
growth-positive
Medtronic, Nutrino update iPro2 myLog app for CGM - Drug Delivery Business
Medtronic and Nutrino have launched an update for the iPro2 myLog app, called the FoodPrint Report, which provides diabetes patients with insights into the link between meals and blood glucose fluctuations. The app uses Nutrinos artificial intelligence platform to assess personal nutrition, allowing patients to photograph each meal or snack during a six-day evaluation. The apps data is synchronized with continuous glucose monitoring data to generate reports on glucose level patterns and score each meal or snack based on blood glucose reaction. Medtronic is expanding its partnership with Nutrino to embed food data and insights across all of its diabetes businesses.
PartnersExpand
growth-positive
Medtronic to set up Israeli R&D centers
Medical equipment company Medtronic will establish a development center in Israel in cooperation with the Israel Innovation Authority. In return for hiring 100 employees, the company will receive a $14 million grant. The new activity will be in two locations: Jerusalem and Yokneam, and will involve brain monitoring and big data for medicine. Medtronic has a deep connection with the Israeli medical equipment industry and has previously acquired Israeli medical equipment companies. The company is also involved in partnerships and investments in Israel. The expansion of Medtronics activity in Israel is seen as a positive growth opportunity for the company.
Expand
growth-positive
Medtronic to open two Israel R&D centers
US medical device giant Medtronic plc is set to open two new R&D centers in Israel, which will employ 80 people. The company plans to invest $56 million in the centers and has requested a government grant of $15 million. Medtronic already has a major presence in Israel with 750 employees following its acquisitions of various medical technology companies. The company aims to be a key player in the life sciences and medical equipment sector in Israel.
InvestmentExpand
growth-positive
"Israel is used to doing more with less"
Medtronic, one of the worlds leading medical equipment companies, has acquired Irish company Covidien, making it the largest medical equipment company in the world. The $50 billion acquisition has expanded Medtronics presence in various medical equipment subsectors. Medtronic has been active in Israel for many years and has acquired several Israeli companies. Dr. Stephen Oesterle, Medtronics senior VP of medicine and technology, has been advocating for cooperation with Israel. The article discusses the challenges of financing in the medical equipment market and the importance of emerging markets for Medtronics growth. The Covidien acquisition has allowed Medtronic to enter new markets and acquire Israeli companies that align with its strategic goals.
AcquisitionPartners
growth-negative
Medtronic moves Ventor's operations overseas
Medtronic is closing heart-valve developer Ventor Technologies in Netanya and transferring its R&D activity to other sites. Ventor, which was acquired by Medtronic for $325 million in 2009, developed minimally-invasive replacement aortic valves. The closure is due to the successful completion of preparatory research and patient recruitment for the clinical trial needed for EU CE Mark certification. The 55 employees at Ventor will be fired, but will receive all benefits due to them by law, as well as additional benefits like job placement services. Ventor CEO Guy Ezekiel will stay on during the closure process.
Layoffs
growth-positive
Medtronic to turn Ventor into major new Israeli R&D center
Medical devices giant Medtronic plans to turn its latest $325 million acquisition, Israeli company Ventor Technologies, into a significant R&D center for new technologies. Medtronic views Ventor as a primary innovation center and wants to learn from their engineering talent. Ventor focuses on developing transcatheter valve technologies for patients suffering from aortic stenosis. Medtronic also announced another $700 million acquisition of heart device maker CoreValve. The deal with Medtronic is seen as a positive sign for the Israeli high-tech industry and the life sciences sector.
AcquisitionExpand
growth-negative
Medtronic buys Odin for $9m
Medical devices giant Medtronic has acquired Israeli start-up Odin Medical Technologies, a developer of MRI systems for brain surgery, for $9 million. Medtronic led Odins third financing round, in which it raised $4 million at a company value of $30-40 million. The net price tag for Odin was reached after deducting the companys debts to the Office of the Chief Scientist and to Medtronic; the gross price was $20 million. The acquisition was not as successful as hoped, leading to a growth-negative impact on Odin Medical Technologies.
AcquisitionInvestmentPartners
